Carrier systems for the treatment of inflammatory bowel disease

Lamprecht, Alf; Stallmach, Andreas; Kawashima, Yasunaru; Lehr, Claus‐Michael

doi:10.1358/dof.2002.027.10.740182

Cited by 17 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With this goal in mind, a wide range of anti-inflammatory pharmaceutical products have been commercialized mainly for oral administration with modified delivery profiles in the gastrointestinal tract (Lamprecht et al, 2002;Podolsky, 2002;Hanauer and Present, 2003). In many cases, pharmacotherapy for IBD consists of life-long administration of one or more of aforementioned drugs.…”

mentioning

confidence: 99%

“…Therefore, quality and severity of adverse effects of these therapeutic regimens is an essential issue to address. Consequently, innovative drug delivery strategies have been designed for more selective delivery of drug to sites of inflamed tissue while reducing the risk for systemic adverse effects (Lamprecht et al, 2002).…”

mentioning

confidence: 99%

“…Some drug delivery systems perform time-dependent drug release. Others, among them most of currently commercialized systems, are based on the change of luminal pH during gastrointestinal passage (Lamprecht et al, 2002). Because these systems are known to exhibit a lack of specificity in terms of drug release, newer strategies were developed to increase selectivity of drug deposition toward inflamed colon tissue.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice

Pellequer

Meißner²,

Ubrich³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice

Pellequer

Meißner²,

Ubrich³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

“…The usually strong adverse effects of anti-inflammatory or immune-suppressant drugs applied under these circumstances may require their strictly local application. Although many efforts have been made for a higher specificity of drug release by designing new drug delivery devices (Lamprecht et al, 2002), all marketed delivery systems still appear to be insufficiently selective (Lamprecht, 2003). This is due to the fact that the drug release mechanisms are based on physiological parameters that are not related to the inflammation and barely to its location.…”

mentioning

confidence: 99%

Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats

Lamprecht

Yamamoto²,

Takeuchi³

et al. 2005

J Pharmacol Exp Ther

169

View full text Add to dashboard Cite

Nanoparticles (NP) are proposed for targeted drug delivery to the inflammation site in severe cases of inflammatory bowel disease where state-of-the-art delivery devices fail. FK506 (tacrolimus) entrapped into NP was administered either orally or rectally to male Wistar rats suffering from a preexisting experimental colitis. Clinical activity score, colon/body weight index, and myeloperoxidase activity were determined to assess the inflammation. Tissue penetration experiments elucidated the processes involved in the proposed new therapeutic approach. The therapeutic effects of FK506 solutions as well as FK506-NP by oral route were minor. The myeloperoxidase activity and colon/body weight ratio decreased significantly (P Ͻ 0.05) only after the rectal administration of FK506-NP, whereas treatment by free drug was not different from colitis control in both 2,4,6-trinitrobenzenesulfonic acid and oxazolone colitis model. NP allows an enhanced and selective drug penetration into the inflammation site as opposed to surrounding healthy tissue (healthy: FK506, 109 Ϯ 18 nmol/cm 2 ; FK506-NP, 51 Ϯ 13 nmol/cm 2 ; colitis: FK506, 79 Ϯ 28 nmol/cm 2 ; FK506-NP, 105 Ϯ 24 nmol/cm 2 ), presumably by protecting the encapsulated drug against influences from efflux systems and mucosal metabolism. The relative drug penetration into the inflamed tissue is about 3-fold higher compared with healthy tissue when using NP as drug carriers. The use of drug-loaded NP offers several advantages compared with standard therapeutic strategies such as a higher selectivity in adhesion to and enhanced drug penetration into the inflamed tissue.

show abstract

“…The release features of these carriers are generally depending on a variety of formulation‐specific parameters. Classic colon delivery systems have been extensively reviewed 38, 41–44. Therefore, we give here only a rough summary of the principal strategies and their therapeutic inefficiencies.…”

Section: Conventional Drug Delivery Strategiesmentioning

confidence: 99%

Alternative Drug Delivery Approaches for the Therapy of Inflammatory Bowel Disease

Meißner

Lamprecht

2008

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Carrier systems for the treatment of inflammatory bowel disease

Cited by 17 publications

References 52 publications

Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice

Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice

Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats

Alternative Drug Delivery Approaches for the Therapy of Inflammatory Bowel Disease

Contact Info

Product

Resources

About